/viestories/media/media_files/2025/02/12/K2tR0ilmD0HVyxksYBtw.png)
Ajanta Pharma Share Price Target
Ajanta Pharma Limited, established in 1973, is an Indian multinational pharmaceutical company with a presence in over 30 countries. Known for its strong stock performance, its future depends on factors like financial health.
/viestories/media/media_files/2025/02/03/6xUSNufI4vmd02Dk19Tx.jpg)
This article will explore Ajanta Pharma's share price target for 2025 and beyond, along with a financial analysis of recent years.
Ajanta Pharma Share Price Target 2025
Explore Ajanta Pharma's share price target for 2025 with monthly projections, including maximum and minimum estimates. Stay informed about expected stock trends to make strategic investment decisions.
| Month (2025) | Maximum Target | Minimum Target |
| January | Rs 3,782.37 | Rs 3,080.06 |
| February | Rs 3,824.90 | Rs 3,117.88 |
| March | Rs 3,907.00 | Rs 3,152.32 |
| April | Rs 4,019.33 | Rs 3,188.40 |
| May | Rs 4,130.81 | Rs 3,225.00 |
| June | Rs 4,241.26 | Rs 3,260.25 |
| July | Rs 4,350.46 | Rs 3,299.45 |
| August | Rs 4,460.77 | Rs 3,335.62 |
| September | Rs 4,572.51 | Rs 3,366.80 |
| October | Rs 4,682.25 | Rs 3,394.27 |
| November | Rs 4,793.25 | Rs 3,428.53 |
| December | Rs 4,910.00 | Rs 3,463.42 |
Know more about the best traders in India.
Ajanta Pharma Share Price Target 2026 to 2030
Discover Ajanta Pharma's projected share price targets from 2026 to 2030, with both maximum and minimum price estimates for each year. Stay updated on potential stock trends to make informed investment decisions.
| Year | Maximum Target | Minimum Target |
| 2026 | Rs 6,134.12 | Rs 3,507.21 |
| 2027 | Rs 7,458.60 | Rs 3,952.53 |
| 2028 | Rs 8,891.02 | Rs 4,403.10 |
| 2029 | Rs 10,611.64 | Rs 4,807.62 |
| 2030 | Rs 12,100.50 | Rs 5,320.91 |
Ajanta Pharma Ltd Competitors
- Ajanta Pharma (m-cap: 41,787 cr INR)
- Sun Pharma m-cap: 456,341 cr INR
- Divis Labs m-cap: 163,057 cr INR
- Cipla m-cap: 128,872 INR
- Torrent Pharma m-cap: 118,356 INR
Conclusion -
Ajanta Pharma's share price has surged by 400% in the past five years, and its prospects remain positive. However, investors should monitor factors like the industry outlook, the company’s financial health, and future plans. Experts from ICICI Direct and Motilal Oswal recommend buying Ajanta Pharma stock for potential growth.
FAQs
Disclaimer:
- The information is based on our understanding of the stock's historical performance.
- Stock market predictions are unpredictable and can change, so expert advice is strongly recommended before investing.
- The values provided are based on predictions and may not be accurate, we recommend verifying the information with other sources.
- For further inquiries about the stock market, please contact us via email.
